Cell Line Development Market Size to Surpass USD 20.9 Bn by 2030

According to the global Cell Line Development market size is expected to surpass around USD 20.9 billion by 2030 from valued at USD 5.17 billion in 2021 and growing at a CAGR of 12.9% from 2022 to 2030.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/7131

Key Takeaways:

• Reagent and media was the largest product market in 2021, owing to the increasing number of cell culture procedures. Reagent and media are necessary components involved in cell line development procedures & cell culture and are cost-intensive in nature. The market for reagent and media was valued at over 4.0 billion in 2021.
• Mammalian cell lines were widely used as a source for cell line development in 2021, owing to associated advantages such as accurate complex protein expression nature, critical for the production of monoclonal antibodies, vaccines, and biologics.
• Cell line development finds the largest application in the bioproduction of biologics, vaccines, Mabs, therapeutic proteins, and biosimilars. Rising demand for monoclonal antibodies and vaccines are expected to boost the growth of this segment over the forecast period. The market for cell line development based bioproduction is also expected to witness lucrative growth of over 13.5% during the forecast period.
• North America was the largest market in 2021, with revenue estimated at over 800 million. The region’s market dominance is attributed to factors such as the growing adoption rates of cell culture techniques, the presence of well-developed healthcare infrastructure, supportive government initiatives and high healthcare expenditure levels.
• Asia Pacific cell line development market is anticipated to register rapid growth over the forecast period owing to factors such as the presence of high unmet needs, rising number of CROs (Contract Research Organization) providing pertinent services, growing R&D investments aimed at the development of stable cell lines and increasing biologics production.

Report Scope of the Cell Line Development Market

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/7131

The growing biopharmaceutical industry is anticipated to drive the demand for cell line development procedures.

 Most of the biopharma companies used cells as an expression host for recombinant monoclonal antibody production. Increase in demand for monoclonal antibodies, cancer therapeutics, and the availability of advanced technologies to produce novel cell lines are expected to propel the market growth in the coming years.

The Increasing demand for monoclonal antibodies and patent expiration of blockbuster biologics are expected to drive the cell line development industry over the forecast period.

Increasing prevalence of autoimmune diseases and cancer is likely to increase the demand for accurate and cost-effective treatment options which is expected to render a positive impact on market growth. In addition, improving healthcare infrastructure, economic development and favorable government initiatives promoting the growth of the biotechnology industry are factors contributing towards the growth of the cell line development market.

Ongoing R&D for stable & authentic cell lines and the introduction of technologically advanced processes such as single-use bioreactor and microbioreactor for large scale bioproduction are further expected to provide this market with lucrative future growth opportunities.

Product Insights

Reagents and media accounted for the largest revenue share as of 2021 due to increasing bio-production that requires these products from incubation to preservation. These products are cost-intensive nature and have repetitive use in the production of biologics hence accounted for the largest revenue share.

Reagents used are attachments and matrix factors, antibiotics, biological buffers, cell freezing, separation and dissociation reagents, and other miscellaneous reagents. Media and salt are essential in bio-production as they provide nutrients to cells and fuel the growth. Some of the most commonly used products are Hans F-10 media, RPMI media, medium 199, MEM media, and DMEM media.

Equipment used are incubators, bioreactors, storage equipment, centrifuge, and microscopes. Bioreactors held the dominant share as of 2014 in the equipment segment due to its usage in large-scale manufacturing of biologics. The introduction of single-use bioreactors is a major driver contributing to the growth of the bioreactor segment over the forecast period. Single-use bioreactors are accompanied by advantages such as cost-effectiveness, time management, and protection against cross-contamination.

On the other hand, the accessories and consumables segment is anticipated to show lucrative growth due to the rising adoption of disposables in these procedures. Increasing laboratory setups for biologics production and R&D activities is attributing to this.

Source Insights

Cell lines development is initiated via organs or tissues collected from mammalians or non-mammalian sources. The source selection is a prerequisite for the development of stable cell lines for commercial purposes. Rising adoption of a mammalian source for the monoclonal antibodies production and the need for expressing complex proteins similar to human beings are expected to boost the adoption of this segment in the coming years.

In addition, enhanced cell engineering and expression systems for this source development are expected to propel the demand.  There are over 4,000 mammalian cell lines available for the use in biologics production and research is going on for the introduction of a few more. This is expected to serve the mammalian source segment with lucrative opportunities.

In general, this technology is based on Glutamine Synthetase (GS) system or methotrexate (MTX) amplification technology. However, the clones produced by these technologies are heterogeneous in nature and hence need to be screened for the selection of stable high productive cell clones and require six to twelve months.

Advancements in clone screening and protein expression in the mammalian source to improve efficiency and speed of producing highly productive cell lines on large-scale production of therapeutic proteins are the factors responsible for segment spearheading.

Type Insights

The recombinant segment accounted for the largest revenue share as of 2021 due to its wide applications in protein interactions, gene activation, and biologics production methods. Furthermore, rising demand for toxicity testing and drug screening are anticipated to fuel the demand in the coming years.

Increase in demand for biologic therapeutics to treat autoimmune disorders, and cancer is the key contributing factor for the high adoption of recombinant proteins during the forecast period. These products are enzymes, blood factors, monoclonal antibodies, hormones, and antibody-related molecules. There are around 650 protein therapeutics approved globally, out of which more than 400 products are recombinant.

Cell line development is an important step in recombinant protein production. The lucrative growth of these proteins due to advancements in expression vector design, clone screening, and cell engineering technologies. Increasing focus on the development of monoclonal cell lines that are stable & consistently expressing the protein with high quality is also expected to fuel the segment growth in the coming years.

Primary cell culture is the fastest-growing segment due to its wide application in genetics, cell morphology, cell metabolism, and physiology. Cell culture is initiated from embryonic, normal, and malignant tissues. From single blood cells, a variety of cells are produced, hence, primary cell cultures are often mixed and grow in in-vitro conditions. The increasing demand for in vitro production of biologics is expected to fuel the demand for this segment during the forecast period.

Application Insights

Cell line development found the largest significance and application in the bio-production of biosimilars, biologics, vaccines, a therapeutic protein, and Mabs. Increasing prevalence of chronic diseases such as cancer and autoimmune diseases is pushing demand for faster and effective therapeutics.

The bioproduction segment accounted for the largest revenue share in 2021 owing to increasing antibiotic and vaccine production. Production of biologics based therapeutic drugs including vaccines, therapeutic proteins, cell therapies, and gene therapies together constitutes the bioproduction application segment. Antibiotics and vaccine production are the most prominent applications of bioproduction and the demand is expected to grow exponentially in the future due to the rise of pandemic and communicable diseases especially in the developing economies.

Currently available vaccines produced by this technology are polio vaccines produced by monkey kidney and neoplastic cell lines. Therapeutic protein is one of the rapidly growing industries due to molecular engineered proteins with optimal target recognition, bio-distribution, pharmacokinetics, and therapeutic functioning.

The bioproduction segment is driven by factors such as increasing in-vitro research activities, safety and efficacy concerns about the product, introduction of biosimilars, and high demand for cellular medicines. Commonly used cell lines for the production of biologics are CHO, GS-knockout CHO-K1, CHO-K1, 293T, HEK293, 293EC18/CRE-Luc, 1321N1, 293EC18, U-2OS, and RH7777 

Regional Insights

North America cell line development business captured over 35% market share in 2021 due to the presence of constant technological developments followed by new discoveries triggering the adoption of novel procedures for bioproduction. The presence of rigorous initiatives conducted by research organizations functioning in this region such as Thermo Fisher Scientific Inc., American Type Culture Collection (ATCC), and Sigma-Aldrich Corporation which provide high-quality biologics services is attributing toward the growth.

In addition, supportive government initiatives and growing awareness pertaining to monoclonal antibodies application in cancer treatment are some of the factors expected to drive the regional industry growth.

Asia Pacific regional market is anticipated to witness lucrative growth owing to increasing expenditure on healthcare by government and private sector companies. The biotechnology industry in developing economies is expected to show significant growth during the forecast period. In the developing economies, government initiatives such as public healthcare programs and improved healthcare infrastructure are contributing to the growth of the biotechnology sector.

For instance, in India, organizations such as the Department of Science and Technology (DST), Department of Scientific & Industrial Research (DSIR) and Department of Biotechnology (DBT) are regulating the production and guidelines for biotechnology products. These organizations provide guidelines related to manufacture or transfer technology, raising funds, and generating manpower for production.  Initiatives like these are expected to fuel the growth over the forecast period.

Some of the prominent players in the Cell Line Development Market include:

 GE Healthcare, Lonza Group AG, Sartorious AG, WuXi AppTec Inc., Sigma-Aldrich Corporation, Selexis SA, Thermo Fisher Scientific Inc., and Corning Inc. Government organizations such as the European Collection of Cell Cultures (ECACC) and American Type Culture Collection (ATCC) are also operating in this industry.

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Cell Line Development market

• Product
  • Reagents and media
  • Equipment
    • Incubators
    • Centrifuges
    • Bioreactors
    • Storage equipment
    • Microscopes
  • Accessories and consumables
• Source
  • Mammalian cell line
  • Non-mammalian cell line
    • Insects
    • Amphibians
• Type of Cell Line
  • Recombinant cell lines
  • Hybridomas
  • Continuous cell lines
  • Primary cell lines
• Application
  • Bioproduction
  • Drug discovery
  • Toxicity testing
  • Tissue engineering
  • Research

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7131

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/